Oncternal Therapeutics Inc ONCT

NAS: ONCT | ISIN: US68236P1075 14/11/2024

1,110 USD (-2,63%)

(-2,63%) 14/11/2024

Grafiek Oncternal Therapeutics Inc

Grafiek Oncternal Therapeutics Inc

1 dag1d -2,63%
1 week1w -12,60%
1 maand1m -8,26%
3 maanden3m -70,79%
6 maanden6m -87,44%
1 jaar1j 241,64%
5 jaar5j -81,68%

Oncternal Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

18 maart 2021 · Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

11 maart 2021 · Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results · Persbericht

22 februari 2021 · Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 januari 2021 · Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors · Persbericht

14 januari 2021 · Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program · Persbericht

7 januari 2021 · Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies · Persbericht

Profiel Oncternal Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.oncternal.com

Hoofdzetel: San Diego, California Verenigde Staten

CEO: James Breitmeyer

Werknemers: 32

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe